The clinicopathological and prognostic significance of telomerase reverse transcriptase (TERT) promoter mutations have been widely investigated in thyroid cancer; however, the results are still discrepant. Systematic searches were performed in PubMed, Web of Science, Scopus, Ovid, and the Cochran Library databases for relevant articles prior to April 2016. Mutation rates were synthesized by R statistical software. The odds ratio or standardized mean difference with 95% confidence interval was pooled by Stata. A total of 22 studies with 4,907 cases were included in this meta-analysis. TERT promoter mutations tended to present in aggressive histological types including poorly differentiated thyroid cancer (33.37%), anaplastic thyroid cancer (38.69%), and tall-cell variant papillary thyroid cancer (30.23%). These promoter mutations were likely to exist in older patients and males and were well associated with larger tumor size, extrathyroidal extension, vascular invasion, lymph node metastasis, distant metastasis, advanced tumor stage, disease recurrence/persistence, and mortality. In addition, TERT promoter mutations (especially C228T) tended to coexist with BRAF V600E mutation, which indicated more aggressive tumor behavior. Therefore, TERT promoter mutations may be promising biomarkers for early diagnosis, risk stratification, prognostic prediction, and management of thyroid cancer.
Introduction
Telomerase, a RNA-dependent DNA polymerase, adds repeat segments to the end of linear chromosomes stabilizing the length of telomere and enabling the immortalization of malignant cells. 1 Telomerase reverse transcriptase (TERT) is a rate-limiting catalytic subunit of telomerase complex taking part in telomerase reactivation and telomere elongation. 2, 3 Overexpression of TERT and activation of telomerase are found in various malignancies, which are linked to cancer hallmarks including proliferation, antiapoptosis, angiogenesis, invasion, and metastasis. 4, 5 Two mutations in -124 bp (chr5: 1,295,228; termed C228T) and -146 bp (chr5: 1,295,250; termed C250T) upstream from the translation start site of TERT gene have been identified in melanomas 6, 7 and have further been found in glioma, 8, 9 liposarcoma, 9 urothelial carcinoma, 8, 10 hepatocellular carcinoma, 8, 11 and thyroid cancers. [12] [13] [14] [15] [16] [17] Functional research studies showed that TERT promoter mutations enhanced the transcriptional activity of the TERT promoter, which highly upregulated the mRNA level and increased telomerase activity.
submit your manuscript | www.dovepress.com
Dovepress

su et al
This may be because both mutations generate novel binding sites (GGAA/T) for E-twenty-six (ETS) transcription factors and enhance the transcriptional level, which provides an alternative mechanism of TERT activation. [6] [7] [8] Thyroid cancer is the most common endocrine malignancy, with an increasing incidence in the last few decades. 18, 19 Among the follicular-cell-derived thyroid cancer (FCDTC), papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) are well-differentiated and classified as differentiated thyroid cancer (DTC), 20 while anaplastic thyroid cancer (ATC) is undifferentiated with limited survival of ,6 months. 21 Another rare histological type is medullary thyroid cancer (MTC) originating from parafollicular or C cells. Development and progression of thyroid cancer are accompanied by accumulation of genetic and epigenetic alterations which vary from different histological types of thyroid cancer. The aberrant activation of RET signaling is the primary mechanism of MTC, while MAPK pathway (mainly triggered by BRAF V600E mutations) and PI3K pathway (which can be caused by mutations in RAS, PTEN, and PIK3CA), respectively, lead to PTC and FTC. 20 TERT promoter mutations also participate in the carcinogenesis of thyroid cancer, and the frequency ranges from 9% to 37% in different studies. [12] [13] [14] 16, 17, 22 Although the clinicopathological and prognostic significance of TERT promoter mutations have been investigated in various research studies, [14] [15] [16] [17] 22, 23 no consistent conclusion has been achieved. 15, [24] [25] [26] Besides, some researchers have reported that the coexistence of BRAF and TERT promoter mutations contributes to more aggressive tumor and worse outcome; 15, 23, 27 however, other researchers have reported contrary results. 24, 28 Therefore, this meta-analysis was conducted to clarify the distribution of TERT promoter mutations in different histological types of thyroid cancer and then analyze their association with high-risk clinicopathological features, adverse outcomes, and BRAF V600E mutation. Furthermore, the practical values of TERT promoter mutations in preoperative diagnosis, risk stratification, prognostic prediction, and therapeutic option were evaluated.
Materials and methods search strategy and selection criteria
Systematic searches were performed in PubMed, Web of Science, Scopus, Ovid, and the Cochran Library databases for relevant studies before April 2016. The search terms were: ((thyroid cancer) or (thyroid neoplasm) or (thyroid tumor)) and ((TERT) or (telomerase reverse transcriptase)). Relevant articles and reviews were also inspected for additional studies. Studies were included according to the following criteria: 1) detecting TERT promoter mutations in thyroid cancer; 2) data availability of mutation rate, clinicopathological features, prognosis, or BRAF V600E mutation; and 3) evaluation of the summary odds ratio (OR) or standardized mean difference (SMD) with 95% confidence interval (CI). Studies were excluded based on these criteria: 1) review, case report, editorial, or comments; and 2) research studies with repeated or unusable data.
Data extraction and quality assessment
Details including first author, year of publication, country, number of centers, study design, number of participants, histological type of thyroid cancer, mean age, gender, sample source, sequencing method, cases and duration of follow-up, BRAF V600E mutation, clinicopathological features (mean diameter of tumor, extrathyroidal extension, vascular invasion, distant metastasis, lymph node metastasis, and tumor stage), and adverse outcome (persistence/ recurrence and disease specific mortality) were obtained from the studies. Tumor stage was standardized by the tumor-node-metastasis (TNM) system of the American Joint Committee on Cancers. 25 Persistence/recurrence was defined as the presence of abnormality confirmed by pathology. The quality of studies was assessed by two investigators according to the Newcastle-Ottawa scale (NOS) comprising three dimensions: four scores for subject selection, two scores for subject comparability, and three scores for prognostic assessment. 26 Studies with .7 scores were regarded as high quality, 4-6 scores were mid-range, and #3 were low quality. 
statistical analysis
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Clinicopathological and prognostic significance of TERT number of studies .10 (both fixed effects model and random effects model). For all analyses, P,0.05 was regarded as statistically significant.
Results
search results and quality assessment
A flowchart of the literature research is shown in Figure 1 . A total of 1,106 articles were initially included. After removal of the duplicates, 894 studies remained. Then, 854 studies were excluded after reviewing the titles and abstracts. Fulltext of the remaining 40 studies were further evaluated, and 22 studies with 4,907 patients were ultimately included in this meta-analysis. [12] [13] [14] [15] [16] [17] 22, 23, 27, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] All the 22 studies reported the frequency of TERT promoter mutations, [12] [13] [14] [15] [16] [17] 22, 23, 27, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] 18 studies were available for analyzing the clinicopathological features and prognostic significance, [14] [15] [16] [17] 22, 23, 27, [31] [32] [33] [35] [36] [37] [38] [39] [40] [41] [42] 15 studies investigated the relationship of TERT promoter and BRAF V600E mutations, 13, 15, 16, 22, 23, 27, [33] [34] [35] [36] [37] [39] [40] [41] [42] and six of them evaluated the synergetic effect of both mutations. 15, 24, 25, 35, 37, 41 According to the NOS system, 11 studies were classified as high-quality and the other 11 were mid-range. Main characteristics and methodological quality of all the 22 studies are listed in Table 1 according to the publication year. The structures of TERT core promoter and BRAF protein kinase are shown in Figure 2 . Table 2 summarized the distribution of TERT promoter mutations in different histological types of thyroid cancer.
Distribution of TERT promoter mutations in thyroid cancer
Random effects model was used in the analysis with obvious heterogeneity (I 2 .50%); otherwise, the fixed effects model was chosen. The TERT promoter mutations only existed in FCDTC, but were absent in MTC and benign lesions (data not shown). Two types of TERT promoter mutation (C228T and C250T) were mutually exclusive. Besides, C228T (0.1126; 95% CI 0.0820-0.1433) was more common than C250T (0.0271; 95% CI 0.0174-0.0368). Their frequencies in poorly differentiated thyroid cancer (PDTC) (0.3337; 95% CI 0.2068-0.4606) and ATC (0.3869; 95% CI 0.2866-0.4872) were three times higher than that in DTC (0.1091; 95% CI 0.0819-0.1363). And the rate in FTC (0.1703; 95% CI 0.1277-0.2128) was nearly twice in PTC (0.0941; 95% CI 0.0716-0.1165). Among the subcategories of PTC, tall-cell PTC (TCPTC, 0.3023; 95% CI 0.1650-0.4396) harbored especially higher rate than conventional (0.0342; 95% CI 0.0362-0.1490) and follicular variant (0.0809; 95% CI 0.0207-0.1824) PTCs.
clinicopathological and prognostic significance of TERT promoter mutations Age, gender, tumor size, extrathyroidal extension, vascular invasion, lymph node metastasis, distant metastasis, tumor stage, persistence/recurrence, and mortality were obtained from the studies 11, 16, 7, 8, 4, 14, 8, 12, 8 , and 5, respectively. Fixed effects model was used in the analysis of gender, vascular invasion, persistence/recurrence, and mortality, while random effects model was chosen for the other analyses.
As shown in Figure 3 , TERT promoter mutations tended to present in older patients (SMD 0.79; 95% CI 0.61-0.96) 
Discussion
The majority of thyroid cancer has excellent prognosis after thyroidectomy with/without radioiodine ablation. 43 However, a small group of patients suffer from unfavorable outcome. 44, 45 During the pathogenesis and progression of thyroid cancer, a number of genetic and epigenetic alterations are accumulated. These alterations provide potential biomarkers to discriminate aggressive cases from those with indolent behavior. In recent years, the clinicopathological and prognostic significance of TERT promoter mutations have been widely evaluated in thyroid cancer, and the discrepancies among studies are probably caused by small sample size of individual studies. [14] [15] [16] [17] 22, 23 This meta-analysis demonstrated that TERT promoter mutations were likely to aggregate in aggressive histological types and associated with high-risk clinicopathological features and adverse outcome of thyroid cancer. The present study also confirmed the coexistence of TERT promoter (C228T) and BRAF V600E mutations, which contributed to more aggressive tumor behavior. De-Tao et al conducted a similar metaanalysis recently, but it only included 8 studies comprising 2,035 patients and excluded studies analyzing fine-needle aspiration biopsy (FNAB) which was an important and reliable diagnostic approach for thyroid cancer. 46 Another study conducted by Liu and Xing also achieved brilliant results. 47 However, almost all of the studies were based on Americans and Europeans, except one from Saudi Arabia. This meta-analysis included five additional studies from Asia, which may be complementary because of the different genetic background among ethnicities.
TERT promoter mutations were exclusively present in FCDTC. Previous researchers propose that TERT promoter mutations usually exist in malignancies originating from terminally differentiated cells with low self-renewing capacity, 9 while the rapidly renewing tissues have alternative mechanisms for telomere elongation and are less dependent on TERT activation. 48 In addition, this study showed that TERT promoter mutations were absent in normal tissues or benign lesions; thus they can serve as biomarkers having high specificity for malignancy. However, the diagnostic efficiency may be severely limited by the low prevalence of TERT promoter mutations in DTC. 30 Liu and Xing and Crescenzi et al, respectively, evaluated the feasibility of TERT promoter mutations in preoperative FNAB and core needle biopsies and found it can improve the diagnostic efficiency for indeterminate nodules. 30, 32, 34 A previous study found that BRAF V600E mutation had no significant value for indeterminate nodules classified as follicular neoplasm/ suspicious for follicular neoplasm (FN/SFN) . 49 In this metaanalysis, the frequencies of TERT promoter mutations in FTC and FVPTC, the main components of malignant FN/SFN nodules, were found to be 17.03% and 8.09%, respectively. Therefore, TERT promoter mutations may be helpful to diagnose thyroid cancer in FN/SFN nodules.
TERT promoter mutations tended to aggregate in aggressive histological types (ATC, PDTC, and TCPTC) and were significantly associated with high-risk features and adverse outcome. Furthermore, the coexistence of BRAF V600E and TERT promoter mutations indicated more aggressive tumor and worse prognosis, and the influence of TERT promoter mutations seemed to be more significant than BRAF V600E mutation. The mechanism underlying the synergetic effect of BRAF and TERT promoter mutations remains uncertain. 15, 24, 25, 29, 30, 39, 50 Vinagre et al and Bullock et al demonstrated that BRAF and TERT promoter mutations can increase the expression of each other, 17, 37 which may be achieved by activation of MAPK pathway and regulation of ETS transcriptional factors. 50 Li et al found that C250T mutation alone was insufficient to drive the transcription of TERT gene and required noncanonical NF-κB signaling for stimulus responsiveness at the same time. 51 Therefore, the functions of C228T and C250T mutations were distinct, which partially explained the result that no significant association was found between BRAF and C250T mutations. Therefore, TERT promoter mutations can distinguish not only malignancy but also aggressive cases that need more positive therapeutic approach and vigilant monitoring. Some researchers also reported that patients with TERT promoter mutations tended to suffer from radiotherapeutic resistance; 39, 52 so TERT promoter mutations might also be potential predictors for therapeutic efficiency.
Limitations
There were some limitations in this meta-analysis. First, most of the studies were retrospectively designed which may cause potential selection bias to better-documented patients and larger tumors since they were more available for collection and analysis. Second, heterogeneity was present in some analyses probably due to confounding factors such as sample size, ethnicity, patients' age, tumor size, sample source, and so on. Besides, most of the aggressive variables are interrelated; so the results should be interpreted cautiously.
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Conclusion
This meta-analysis confirmed that TERT promoter mutations were more frequent in aggressive histological types of thyroid cancer. And they were likely to present in older patients and males and strongly associated with larger tumor size, extrathyroidal extension, vascular invasion, lymph node metastasis, distant metastasis, advanced tumor stage, disease recurrence/persistence, and mortality. TERT promoter mutations seemed to coexist with BRAF mutation, which contributed to more aggressive tumor and worse prognosis. Therefore, TERT promoter mutations have the potential to serve as biomarkers assisting preoperative diagnosis, risk stratification, prognostic prediction, and individualizing therapeutic option or follow-up design of thyroid cancer.
